Mesoblast (NASDAQ:MESO) has implemented a sweeping reorganization of its Board of Directors, effective January 1, 2026, signaling a definitive shift from a research-heavy biotech to a revenue-driven commercial entity.
The leadership transition follows the company's most transformational period, highlighted by the December 2024 FDA approval and subsequent 2025 launch of Ryoncil (remestemcel-L).
Evotec SE (NASDAQ: EVO) announced on January 2, 2026, the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.
In this newly created strategic role, Dr. Fakih will lead an integrated function designed to synchronize Evotec’s corporate messaging with its capital markets strategy.
FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.
Corcept Therapeutics (NASDAQ:CORT) shares plunged Wednesday after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for relacorilant, a treatment for hypertension caused by excessive cortisol levels.
Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.
Axsome Therapeutics (NASDAQ:AXSM) is poised to file for U.S. regulatory approval of its narcolepsy treatment, AXS-12, following a successful pre-New Drug Application (NDA) meeting with the Food and Drug Administration.
MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), completed its acquisition of PineBridge Investments on Tuesday, creating a combined investment powerhouse with approximately $734.7 billion in assets under management.
AtaiBeckley (NASDAQ:ATAI) has officially completed its redomiciliation from the Netherlands to Delaware, finalizing a corporate overhaul that follows the recent strategic combination of atai Life Sciences and Beckley Psytech.
Vanda Pharmaceuticals (NASDAQ:VNDA) has secured U.S. Food and Drug Administration approval for NEREUS™ (tradipitant), ending a four-decade drought in new pharmacological treatments for motion sickness.
Measles cases in the United States have climbed to their highest level in decades as health officials warn of new exposures and falling vaccination rates.
FTAI Aviation (NASDAQ:FTAI) saw its shares rise by 8.8% in the morning session after announcing the launch of FTAI Power, a new venture aimed at repurposing its CFM56 aircraft engines into 25-megawatt power turbines.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced positive findings from its Phase 1b clinical study GLP-1-H24-4, a 12-week chronic trial focusing on its DehydraTECH™ (DHT) delivery platform in comparison to the Rybelsus® control arm.
